Deka Bank Deutsche Girozentrale Aurinia Pharmaceuticals Inc. Transaction History

Deka Bank Deutsche Girozentrale

  • $53.9 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024
SELL
$4.93 - $9.31 $57,227 - $108,070
-11,608 Reduced 60.81%
7,480 $36,000
Q4 2023

Jan 24, 2024
BUY
$7.13 - $9.49 $75,863 - $100,973
10,640 Added 125.95%
19,088 $172,000
Q3 2023

Nov 13, 2023
BUY
$7.77 - $12.27 $65,640 - $103,656
8,448 New
8,448 $65,000
Q1 2022

Apr 28, 2022
BUY
$10.05 - $22.48 $46,230 - $103,408
4,600 Added 10.09%
50,200 $622,000
Q4 2020

Mar 12, 2021
BUY
$12.94 - $16.05 $112,578 - $139,635
8,700 Added 23.58%
45,600 $623,000
Q3 2020

Oct 29, 2020
BUY
$13.19 - $16.66 $486,711 - $614,754
36,900 New
36,900 $518,000

Others Institutions Holding AUPH

# of Institutions
209
Shares Held
58.7M
Call Options Held
1.14M
Put Options Held
1.51M
View Full List

About Aurinia Pharmaceuticals Inc.

AUPH Quotes by TradingView
  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.15B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email